Altanta, GANCT06386874Now EnrollingIRB Ready

Ischemic Stroke Clinical Trial in Altanta, GA

Access cutting-edge ischemic stroke treatment through this clinical trial at a research site in Altanta. Study-provided care at no cost to qualified participants.

Sponsored by BrainQ Technologies Ltd.

Quick Self-Assessment

See if you qualify for this Altanta location

Preparing your pre-screening questions…

Expert Care in Altanta

Access ischemic stroke specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ischemic stroke treatment provided free

Apply for This Altanta Location

Check if you qualify for this ischemic stroke clinical trial in Altanta, GA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Altanta

    Convenient for GA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Altanta site if eligible
  4. 4Begin participation

About This Ischemic Stroke Study in Altanta

This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment. The Q Therapeutic System (BQ 3.0) is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. The Q Therapeutic System (BQ 3.0) is indicated for adjunctive use in a clinical facility or home setting, in addition to standard-of-care therapies. * In Stage 1 (starting 4-21 days after the index stroke event to day 90 post stroke), participants will be randomly assigned (1:1) to receive either active or the sham treatments, up to 5 times a week, and at least to a total of 45 treatments. * In Stage 2 (day 90 to day 180 post stroke), participants in both the active and the control group will be allowed to continue to receive active treatments, up to 5 times per week. * In stage 3 (day 180 to day 270 post stroke), participants will not receive any treatments and would be followed up until the final visit at day 270. Each session will last approximately 60 minutes, with stimulation activated for up to 40 minutes, in conjunction with a home-based exercise program. Treatments may be administered in the hospital, in the clinic or in a home setting. The study will enroll 100-122 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using the BQ 3.0 system.

Sponsor: BrainQ Technologies Ltd.

Who Can Participate

Inclusion Criteria

mRS score of 3 or 4.
FMA-UE score between 10-45 (inclusive) of impaired limb.
SAFE score \>0.
Age 22 to 80 years of age (inclusive).
Diagnosed with an ischemic stroke, confirmed by CT4 or MRI5 imaging.
First ever ischemic stroke, or a recurring ischemic stroke6 occurring at least 3 months after the previous stroke (any stroke), without residual neurological impairment or disability before current stroke.
Four to 21 days from stroke onset (or last known well).
Pre-stroke mRS of 0.
Able to sit with the investigational device for 40 consecutive minutes, in the opinion of the investigator or designee.
Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me".
Willingness to participate in an exercise activity during study intervention sessions.
Availability of a relative or other caregiver able to assist in operating an application installed on a mobile device, including a video call, and assist the participant with the exercising program.
If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of contraception during the study
Informed consent signed by subject.

Exclusion Criteria

Hemineglect impairment (NIHSS item 11, score \>0).
Implanted active electronic or passive MR-incompatible devices.
Pre-existing major neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or pre-existing physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or any epileptic seizure in the last 5 years
Significant visual disturbances, pre-existing or resulting from the index stroke, that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
Unstable serious illness/condition (eg, active cancer, severe heart failure, active major psychiatric condition) or life expectancy of less than 12 months.
A known severe allergic reaction to acrylic-based adhesives.
Alcohol abuse and/or illicit drug abuse in the past 6 months, which is likely to influence ability to fully participate in the trial.
Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
Employee of the Sponsor.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Altanta?

Yes, this clinical trial (NCT06386874) has an active research site in Altanta, GA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ischemic Stroke Treatment Options in Altanta, GA

If you're searching for ischemic stroke treatment options in Altanta, GA, this clinical trial (NCT06386874) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Altanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ischemic stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ischemic stroke clinical trials near you to find additional studies recruiting in your area.

More Stroke Trials in Altanta, GA

See all stroke clinical trials recruiting in Altanta — not just this study.

Browse Stroke Trials in Altanta →

Browse More Trials by Condition

Stroke TrialsHeart Attack TrialsInterstitial Cystitis TrialsMyocardial Infarction TrialsAll Conditions →

Ready to Join in Altanta?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Altanta, GA